Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for XERS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 1.943M
March 31, 2026 -8.837M
December 31, 2025 -0.266M
September 30, 2025 13.85M
June 30, 2025 0.942M
March 31, 2025 -3.137M
December 31, 2024 0.398M
September 30, 2024 -0.083M
June 30, 2024 0.659M
March 31, 2024 35.19M
December 31, 2023 -0.049M
September 30, 2023 -0.072M
June 30, 2023 0.556M
March 31, 2023 -0.863M
December 31, 2022 49.16M
September 30, 2022 -0.187M
June 30, 2022 0.31M
March 31, 2022 78.19M
December 31, 2021 0.125M
Date Value
September 30, 2021 0.001M
June 30, 2021 0.46M
March 31, 2021 26.66M
December 31, 2020 3.326M
September 30, 2020 13.06M
June 30, 2020 69.61M
March 31, 2020 40.07M
December 31, 2019 1.97M
September 30, 2019 22.57M
June 30, 2019 -0.157M
March 31, 2019 56.15M
December 31, 2018 0.029M
September 30, 2018 13.18M
June 30, 2018 90.80M
March 31, 2018 24.20M
December 31, 2017 5.467M
September 30, 2017 0.019M
June 30, 2017 30.02M
March 31, 2017 -0.368M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Zevra Therapeutics, Inc. 1.585M
Aclaris Therapeutics, Inc. 0.091M
ANI Pharmaceuticals, Inc. -4.647M
Corcept Therapeutics, Inc. -2.037M
Veru, Inc. -0.0519M